CareDx to Participate in Upcoming Investor Conferences

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences.

CareDx’s management is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 8, 2023, at 8:00 AM PT / 11:00 AM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.

CareDx’s management will also be presenting at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13th, 2023, at 4:40 PM PT / 7:40 PM ET. To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredxinc.com.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.26
-4.74 (-1.87%)
AAPL  270.31
+1.26 (0.47%)
AMD  251.56
-8.09 (-3.12%)
BAC  53.46
-0.10 (-0.19%)
GOOG  278.13
-5.99 (-2.11%)
META  627.53
-10.18 (-1.60%)
MSFT  513.66
-3.37 (-0.65%)
NVDA  198.93
-7.95 (-3.84%)
ORCL  245.72
-12.13 (-4.70%)
TSLA  446.18
-22.19 (-4.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.